针对 PDAC 的个体化 mRNA 疫苗免疫原性。
Personalized mRNA Vaccine Immunogenic against PDAC.
出版信息
Cancer Discov. 2023 Jul 7;13(7):1504. doi: 10.1158/2159-8290.CD-NB2023-0038.
Abstract
BioNTech's personalized mRNA vaccine, autogene cevumeran, elicited neoantigen-specific T cells in eight of 16 patients with surgically resected pancreatic ductal adenocarcinoma, leading to T-cell expansion in the bloodstream and delays in disease recurrence, according to phase I trial data. A randomized follow-up study is planned.
摘要
辉瑞公司的个体化 mRNA 疫苗 autogene cevumeran，在 16 名接受手术切除的胰腺导管腺癌患者中的 8 名中引发了新抗原特异性 T 细胞，导致血液中 T 细胞扩增，并延迟疾病复发，根据 I 期试验数据。计划进行一项随机随访研究。
Zotero 插件